SCHEMBL5888115

SCHEMBL5888115

COc1ccc(Cn2c(=O)ccc3c(C)nc(N4CCCC4CO)nc32)cc1Cl

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 6/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5888109 1.00 PDE5A (0.48) PDE5A
SCHEMBL5888252 0.90 PDE5A (0.42) PDE5A
SCHEMBL5888247 0.90 PDE5A (0.42) PDE5A
SCHEMBL5888000 0.87 PDE5A (0.55) PDE5A
SCHEMBL5888009 0.87 PDE5A (0.55) PDE5A
SCHEMBL5888012 0.86 PDE5A (0.54) PDE5A
SCHEMBL5888019 0.86 PDE5A (0.54) PDE5A
SCHEMBL5888325 0.84 PDE5A (0.47) PDE5A
SCHEMBL5888330 0.84 PDE5A (0.47) PDE5A
SCHEMBL5888125 0.81 PDE5A (0.55) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078522-B2 Pyridopyrimidine or naphthyridine derivative TANABE SEIYAKU CO., LTD. (JP) 2006-07-18 — — US disclosed
US-20050101615-A1 Pyridopyrimidine or naphthyridine derivative TANABE SEIYAKU CO., LTD. (JP) 2005-05-12 — — US disclosed
EP-1364950-A1 PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 2003-11-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101615-A1 Pyridopyrimidine or naphthyridine derivative PDE5A, PDE3B, PDE3A PDE5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback